Neuphoria Therapeutics (NEUP) to Release Earnings on Wednesday

Neuphoria Therapeutics (NASDAQ:NEUP) is projected to issue its Q4 2026 results before the market opens on Wednesday, September 2nd. Analysts expect Neuphoria Therapeutics to post earnings of ($0.56) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, September 30, 2026 at 4:00 PM ET.

Neuphoria Therapeutics Stock Performance

Shares of NEUP stock opened at $3.76 on Monday. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40. The firm’s fifty day simple moving average is $3.81 and its 200 day simple moving average is $4.36. The firm has a market capitalization of $20.32 million, a P/E ratio of -0.34 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 25th. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $21.00.

Institutional Trading of Neuphoria Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC acquired a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at about $43,000. XTX Topco Ltd acquired a new position in Neuphoria Therapeutics in the fourth quarter worth about $47,000. Persistent Asset Partners Ltd raised its position in Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after purchasing an additional 8,495 shares in the last quarter. Boothbay Fund Management LLC bought a new position in Neuphoria Therapeutics during the fourth quarter worth about $54,000. Finally, Bridgeway Capital Management LLC bought a new position in Neuphoria Therapeutics during the fourth quarter worth about $57,000. 15.90% of the stock is currently owned by institutional investors.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.